An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With Atypical Hemolytic-Uremic Syndrome (aHUS Registry)
An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With Atypical Hemolytic-Uremic Syndrome (aHUS Registry)
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
The study will capture post-marketing safety data on patients treated with eculizumab or ravulizumab. Additionally, the study will collect information on the progression of disease in all patients.
Inclusion Criteria:
Exclusion Criteria:
clinicaltrials@alexion.com1-855-752-2356
Dongan, Chungcheongnam-do 31151, South Korea
Jeju-do, 63241, South Korea
Jeollabuk-do, 54907, South Korea
Surich, 8091, Switzerland